Navigation Links
Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA
Date:10/27/2008

New Data on Ceftaroline, a Novel, Broad-Spectrum Cephalosporin in Development for Complicated Skin and Skin Structure Infections (cSSSI) and Community Acquired Pneumonia (CAP)

WASHINGTON, Oct. 27, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) presented a detailed analysis of CANVAS I, a globally conducted, multi-center, Phase III clinical trial, at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America 46th Annual Meeting (ICAAC / IDSA) in Washington, DC. The results of this 702 patient study demonstrated that ceftaroline monotherapy achieved its primary endpoint of non-inferiority versus the combination of vancomycin and aztreonam in the treatment of complicated skin and skin structure infections (cSSSI).(1)

(LOGO: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

Forest also presented eighteen abstracts on data from preclinical studies that demonstrate the activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA), multi-drug resistant Streptococcus pneumoniae (MDRSP) and many gram-negative pathogens in both in vitro and in vivo models of infection.

Results of the CANVAS I study presented on Sunday show that ceftaroline-treated patients had a clinical cure rate of 91.1% compared to a vancomycin-plus-aztreonam clinical cure rate of 93.3% at the test of cure (TOC) visit in the clinically evaluable population (CE). In the modified-intent-to-treat (MITT) population, ceftaroline-treated patients had a clinical cure rate of 86.6% compared to a vancomycin-plus-aztreonam clinical cure rate of 85.6%. The study was de
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
2. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
3. Positive Preclinical Data on Cell Therapy for Spinal Disc Repair Presented at 23rd Annual Meeting of the North American Spine Society
4. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
5. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
8. Kuvan Receives Positive Opinion From CHMP for European Approval
9. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
10. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
11. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas City Animal Health ... animal health companies to hear from animal health companies with the newest technology. ... licensing agreements or distribution contracts. This meeting is one of the only ...
(Date:8/27/2015)... - Portage Biotech Inc. ("Portage") (OTC Market: PTGEF, ... Company Limited (Biohaven), announced today that dosing has ... a glutamate modulating agent. Biohaven filed an investigational ... clearance from the U.S. Food and Drug Administration ... 54% equity interest in Biohaven, a private company. ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... six-month periods ended June 30, 2015. Biorem,s complete second quarter financial ... FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended , ... 2014 , 2015 , 2014 Revenue , ... , 4,433 Gross profit , 1,656 , ...
(Date:8/27/2015)... ... 27, 2015 , ... Inc. Magazine released its annual list of the 5,000 ... in growth for the three years through 2014. Being named to the Inc. 5000 ... in the country. , “We are thrilled to make the Inc. 5000 list ...
Breaking Biology Technology:VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3
... Fibrillation, EP Mapping and ... PCI and Additional Complex Procedures, ST. LOUIS, ... announced today that more than 10,000 procedures have ... utilizes,advanced, magnet-guided navigational technology intended to help,electrophysiologists and ...
... is showcasing its,motion management systems at this year,s ... 8-13, 2007, at the Palau de,Congresos de Catalunya ... motion management and patient positioning at the,Elekta booth ... "Holding still for 10 minutes? Bet you ...
... SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) today provided ... Novartis focused on the development and commercialization of,BCR-ABL ... and drug resistant,Chronic Myelogenous Leukemia (CML). Under ... number of,potential drug candidates, with the anticipated timeline ...
Cached Biology Technology:Stereotaxis' Niobe System Used to Perform More Than 10,000 Procedures Worldwide 2Stereotaxis' Niobe System Used to Perform More Than 10,000 Procedures Worldwide 3Elekta Brings Intelligent Ways to Manage Motion During Cancer Treatment to ESTRO 2SGX Provides Update on BCR-ABL Collaboration 2SGX Provides Update on BCR-ABL Collaboration 3
(Date:8/4/2015)... 04, 2015 ... announced the addition of the "Digital ... Service), Sub-Segment (Computer Forensics, Network Forensics, Mobile ... Service, Vertical and Region - Global Forecast ... By Component (Hardware, Software, and ...
(Date:7/31/2015)... -- Den 10. internationale konference om Genomik (ICG-10, ... 25. oktober i Shenzhen , Kina. ... år. Siden starten i 2006 er ICB blevet en ... er en af de mest dynamiske, entusiastiske og sjove ... gennembrud og fremskridt inden for ,omik,-forskning, som yderligere vil ...
(Date:7/31/2015)... , Chine, 31 juillet 2015 La ... www.icg-10.org ) sera organisée par le BGI du ... Shenzhen en Chine. La ... son inauguration en 2006, l,ICG est devenue l,une ... le domaine des « omiques » et c,est aussi la ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... The December 2009 issue of the Journal ... Christopher Ahern (The University of British Columbia, Vancouver) and ... other K+ channels using in vivo nonsense suppression technology. ... www.jgp.org ). According to Riccardo Olcese (UCLA) in ...
... of New Hampshire assistant professors have received prestigious ... (CAREER) grants. Vaughn Cooper of the department of ... to better understand beneficial mutations in bacteria by ... White of the mechanical engineering department received $400,000 ...
... general rule among mammals that larger males sire more ... Coltman has found a genetic quirk that might make ... Big, heavy males mountain goats shove lightweight Romeos ... males pass their physical attributes and mating success to ...
Cached Biology News:2 UNH faculty receive $1.4M in CAREER grants from NSF 2
... thermostable DNA polymerase obtained by high level ... in E. coli, Concentration: 5U/ul, Applications: Standard ... Scientific, the world leader in serving science. ... the world healthier, cleaner and safer by ...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
... is a thermostable DNA polymerase derived ... at temperatures above 70°C, it was ... PCR and remains the predominant enzyme ... an intrinsic 5'?3' structure-dependent exonuclease activity, ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (F1676) or contact customer s...
Biology Products: